Juno Therapeutics (JUNO) Gains on Kite Pharma News

September 26, 2016 4:05 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Juno Therapeutics (NASDAQ: JUNO) gains after-hours following positive trial news from rival Kite Pharma, Inc., (Nasdaq: KITE). Shares are up 8.6%.

Kite announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19, in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL). KTE-C19 met the primary endpoint of objective response rate (ORR), p<0.0001, with ORR of 76 percent, including 47 percent complete remissions (CR). KITE is halted.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment